210 related articles for article (PubMed ID: 22642738)
61. Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis.
Pulicken M; Bash CN; Costello K; Said A; Cuffari C; Wilterdink JL; Rogg JM; Mills P; Calabresi PA
Mult Scler; 2005 Apr; 11(2):169-74. PubMed ID: 15794390
[TBL] [Abstract][Full Text] [Related]
62. Multiple sclerosis, interferon beta-1b and depression A prospective investigation.
Feinstein A; O'Connor P; Feinstein K
J Neurol; 2002 Jul; 249(7):815-20. PubMed ID: 12140662
[TBL] [Abstract][Full Text] [Related]
63. Local reactions after subcutaneous injections of beta-interferon.
van Rengen A; Goossens A
Contact Dermatitis; 1998 Oct; 39(4):209. PubMed ID: 9817241
[No Abstract] [Full Text] [Related]
64. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment.
Blake G; Murphy S
Neurology; 1997 Dec; 49(6):1747-8. PubMed ID: 9409387
[No Abstract] [Full Text] [Related]
65. [A short history of beta-interferon therapy of multiple sclerosis].
Stock G; Horowski R
Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
[TBL] [Abstract][Full Text] [Related]
66. Early use of interferon beta patients with multiple sclerosis.
Bosley EB; Capildeo R
Int J Clin Pract Suppl; 2002 Sep; (131):17-22. PubMed ID: 12564808
[TBL] [Abstract][Full Text] [Related]
67. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
[TBL] [Abstract][Full Text] [Related]
68. Cutaneous ulcerations following subcutaneous interferon beta injection to a patient with multiple sclerosis.
Inafuku H; Kasem Khan MA; Nagata T; Nonaka S
J Dermatol; 2004 Aug; 31(8):671-7. PubMed ID: 15492442
[TBL] [Abstract][Full Text] [Related]
69. [The use of beta-interferon-1b in children and adolescents with multiple sclerosis].
Bykova OV; Kuzenkova LM; Maslova OI
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):29-33. PubMed ID: 17069059
[TBL] [Abstract][Full Text] [Related]
70. [Interaction between melilot and acenocoumarol? (Melilotruscus aculeatus)].
Chiffoleau A; Huguenin H; Veyrac G; Argaiz V; Dupe D; Kayser M; Bourin M; Jolliet P
Therapie; 2001; 56(3):321-2. PubMed ID: 11475815
[No Abstract] [Full Text] [Related]
71. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
Federal service on surveillance in healthcare and social development (Roszdravnadzor)
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
[No Abstract] [Full Text] [Related]
72. Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis.
Serarslan G; Okuyucu E; Melek I; Hakverdi S; Duman T
Mult Scler; 2008 Mar; 14(2):259-61. PubMed ID: 18337427
[TBL] [Abstract][Full Text] [Related]
73. Severe septal panniculitis in a multiple sclerosis patient treated with interferon-beta.
Mazzon E; Guarneri C; Giacoppo S; Rifici C; Tchernev G; Polimeni G; Wollina U
Int J Immunopathol Pharmacol; 2014; 27(4):669-74. PubMed ID: 25572749
[TBL] [Abstract][Full Text] [Related]
74. Cutaneous necrosis associated with recombinant interferon injection. Report of three cases with interferon beta-1b and review of the literature.
Weinberg JM; Wolfe JT; Sood S; Saruk M; Rook AH; Spiers EM
Acta Derm Venereol; 1997 Mar; 77(2):146-8. PubMed ID: 9111829
[TBL] [Abstract][Full Text] [Related]
75. Local reactions associated with subcutaneous injections of both beta-interferon 1a and 1b.
García-F-Villalta M; Daudén E; Sánchez J; Fraga J; Ramo C; García-Díez A
Acta Derm Venereol; 2001 May; 81(2):152. PubMed ID: 11501663
[No Abstract] [Full Text] [Related]
76. Efficacy and safety of prolonged immunomodulatory treatment with interferon beta.
Demina TL; Khachanova NV; Davydovskaya MV; Popova NF; Gusev EI
Neurosci Behav Physiol; 2009 Jun; 39(5):497-9. PubMed ID: 19430980
[No Abstract] [Full Text] [Related]
77. Electrophysiological, neuropsychological and clinical findings in multiple sclerosis patients receiving interferon beta-1b: a 1-year follow-up.
Gerschlager W; Beisteiner R; Deecke L; Dirnberger G; Endl W; Kollegger H; Lindinger G; Vass K; Lang W
Eur Neurol; 2000; 44(4):205-9. PubMed ID: 11096218
[TBL] [Abstract][Full Text] [Related]
78. Cutaneous necrosis associated with recombinant interferon injection.
Weinberg JM
J Am Acad Dermatol; 1998 Nov; 39(5 Pt 1):807-8. PubMed ID: 9810903
[No Abstract] [Full Text] [Related]
79. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns.
O'Rourke KE; Hutchinson M
Mult Scler; 2005 Feb; 11(1):46-50. PubMed ID: 15732266
[TBL] [Abstract][Full Text] [Related]
80. Delayed occurrence of a severe cutaneous reaction in a multiple sclerosis patient taking interferon beta-1b.
Cohen BA; Greenberger PA; Saini S
Allergy Asthma Proc; 1998; 19(2):85-8. PubMed ID: 9578917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
